Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,085
archived clinical trials in
Cervical Cancer

Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  1/9/2018
Saint Vincent Hospital and Health Care Center
mi
from
Indianapolis, IN
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 1/9/2018
Saint Vincent Hospital and Health Care Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  1/9/2018
McFarland Clinic PC-William R Bliss Cancer Center
mi
from
Ames, IA
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 1/9/2018
McFarland Clinic PC-William R Bliss Cancer Center
mi
from
Ames, IA
Click here to add this to my saved trials
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  1/9/2018
Iowa-Wide Oncology Research Coalition NCORP
mi
from
Des Moines, IA
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 1/9/2018
Iowa-Wide Oncology Research Coalition NCORP
mi
from
Des Moines, IA
Click here to add this to my saved trials
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  1/9/2018
Medical Oncology and Hematology Associates-Des Moines
mi
from
Des Moines, IA
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 1/9/2018
Medical Oncology and Hematology Associates-Des Moines
mi
from
Des Moines, IA
Click here to add this to my saved trials
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  1/9/2018
Medical Oncology and Hematology Associates-Laurel
mi
from
Des Moines, IA
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 1/9/2018
Medical Oncology and Hematology Associates-Laurel
mi
from
Des Moines, IA
Click here to add this to my saved trials
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  1/9/2018
University of Iowa - Holden Comprehensive Cancer Center
mi
from
Iowa City, IA
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 1/9/2018
University of Iowa - Holden Comprehensive Cancer Center
mi
from
Iowa City, IA
Click here to add this to my saved trials
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  1/9/2018
Michigan Cancer Research Consortium NCORP
mi
from
Ann Arbor, MI
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 1/9/2018
Michigan Cancer Research Consortium NCORP
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  1/9/2018
Beaumont Hospital-Dearborn
mi
from
Dearborn, MI
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 1/9/2018
Beaumont Hospital-Dearborn
mi
from
Dearborn, MI
Click here to add this to my saved trials
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  1/9/2018
Saint Mary Mercy Hospital
mi
from
Livonia, MI
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 1/9/2018
Saint Mary Mercy Hospital
mi
from
Livonia, MI
Click here to add this to my saved trials
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  1/9/2018
Saint Joseph Mercy Oakland
mi
from
Pontiac, MI
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 1/9/2018
Saint Joseph Mercy Oakland
mi
from
Pontiac, MI
Click here to add this to my saved trials
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  1/9/2018
Lake Huron Medical Center
mi
from
Port Huron, MI
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 1/9/2018
Lake Huron Medical Center
mi
from
Port Huron, MI
Click here to add this to my saved trials
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  1/9/2018
Cancer Research for the Ozarks NCORP
mi
from
Springfield, MO
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 1/9/2018
Cancer Research for the Ozarks NCORP
mi
from
Springfield, MO
Click here to add this to my saved trials
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  1/9/2018
Cox Medical Center South
mi
from
Springfield, MO
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 1/9/2018
Cox Medical Center South
mi
from
Springfield, MO
Click here to add this to my saved trials
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  1/9/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 1/9/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  1/9/2018
UNC Lineberger Comprehensive Cancer Center
mi
from
Chapel Hill, NC
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 1/9/2018
UNC Lineberger Comprehensive Cancer Center
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  1/9/2018
Carolinas Medical Center / Levine Cancer Institute
mi
from
Charlotte, NC
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 1/9/2018
Carolinas Medical Center / Levine Cancer Institute
mi
from
Charlotte, NC
Click here to add this to my saved trials
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  1/9/2018
Southeast Clinical Oncology Research (SCOR) Consortium NCORP
mi
from
Winston-Salem, NC
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 1/9/2018
Southeast Clinical Oncology Research (SCOR) Consortium NCORP
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  1/9/2018
Oklahoma Cancer Specialists and Research Institute-Tulsa
mi
from
Tulsa, OK
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 1/9/2018
Oklahoma Cancer Specialists and Research Institute-Tulsa
mi
from
Tulsa, OK
Click here to add this to my saved trials
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  1/9/2018
Reading Hospital
mi
from
West Reading, PA
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 1/9/2018
Reading Hospital
mi
from
West Reading, PA
Click here to add this to my saved trials
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  1/9/2018
Women and Infants Hospital
mi
from
Providence, RI
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 1/9/2018
Women and Infants Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
The FIRSTT: Comparing MRgFUS(MR-guided Focused Ultrasound) Versus UAE (Uterine Artery Embolization)for Uterine Fibroids.
The FIRSTT Study: Comparing Focused Ultrasound and Uterine Artery Embolization for Uterine Fibroids
Status: Enrolling
Updated:  1/10/2018
Duke University Health System
mi
from
Durham, NC
The FIRSTT: Comparing MRgFUS(MR-guided Focused Ultrasound) Versus UAE (Uterine Artery Embolization)for Uterine Fibroids.
The FIRSTT Study: Comparing Focused Ultrasound and Uterine Artery Embolization for Uterine Fibroids
Status: Enrolling
Updated: 1/10/2018
Duke University Health System
mi
from
Durham, NC
Click here to add this to my saved trials
The FIRSTT: Comparing MRgFUS(MR-guided Focused Ultrasound) Versus UAE (Uterine Artery Embolization)for Uterine Fibroids.
The FIRSTT Study: Comparing Focused Ultrasound and Uterine Artery Embolization for Uterine Fibroids
Status: Enrolling
Updated:  1/10/2018
University of California at San Francisco
mi
from
San Francisco, CA
The FIRSTT: Comparing MRgFUS(MR-guided Focused Ultrasound) Versus UAE (Uterine Artery Embolization)for Uterine Fibroids.
The FIRSTT Study: Comparing Focused Ultrasound and Uterine Artery Embolization for Uterine Fibroids
Status: Enrolling
Updated: 1/10/2018
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
The FIRSTT: Comparing MRgFUS(MR-guided Focused Ultrasound) Versus UAE (Uterine Artery Embolization)for Uterine Fibroids.
The FIRSTT Study: Comparing Focused Ultrasound and Uterine Artery Embolization for Uterine Fibroids
Status: Enrolling
Updated:  1/10/2018
The Mayo Clinic
mi
from
Rochester, MN
The FIRSTT: Comparing MRgFUS(MR-guided Focused Ultrasound) Versus UAE (Uterine Artery Embolization)for Uterine Fibroids.
The FIRSTT Study: Comparing Focused Ultrasound and Uterine Artery Embolization for Uterine Fibroids
Status: Enrolling
Updated: 1/10/2018
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Bevacizumab in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Bevacizumab (NCI-Supplied Agent: NSC# 704865, IND # 7921) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  1/10/2018
Gynecologic Oncology Group
mi
from
Philadelphia, PA
Bevacizumab in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Bevacizumab (NCI-Supplied Agent: NSC# 704865, IND # 7921) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 1/10/2018
Gynecologic Oncology Group
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Does 3D Laparoscopy Improve Vaginal Cuff Suture Time?
Does 3D Laparoscopy Improve Vaginal Cuff Suture Time? A Randomized Controlled Trial Comparing 3D Laparoscopy Versus Standard Laparoscopy
Status: Enrolling
Updated:  1/18/2018
Brigham and Women's Hosp
mi
from
Boston, MA
Does 3D Laparoscopy Improve Vaginal Cuff Suture Time?
Does 3D Laparoscopy Improve Vaginal Cuff Suture Time? A Randomized Controlled Trial Comparing 3D Laparoscopy Versus Standard Laparoscopy
Status: Enrolling
Updated: 1/18/2018
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Does 3D Laparoscopy Improve Vaginal Cuff Suture Time?
Does 3D Laparoscopy Improve Vaginal Cuff Suture Time? A Randomized Controlled Trial Comparing 3D Laparoscopy Versus Standard Laparoscopy
Status: Enrolling
Updated:  1/18/2018
Odense University Hospital
mi
from
Odense,
Does 3D Laparoscopy Improve Vaginal Cuff Suture Time?
Does 3D Laparoscopy Improve Vaginal Cuff Suture Time? A Randomized Controlled Trial Comparing 3D Laparoscopy Versus Standard Laparoscopy
Status: Enrolling
Updated: 1/18/2018
Odense University Hospital
mi
from
Odense,
Click here to add this to my saved trials
Vietnamese Women's Health Project III
Community Based Participatory Research to Understanding Symptom Perception, Preventive Care-Seeking, and Their Impact on Cervical Cancer Screening Among Vietnamese American Women
Status: Enrolling
Updated:  1/25/2018
OHSU Knight Cancer Institute
mi
from
Portland, OR
Vietnamese Women's Health Project III
Community Based Participatory Research to Understanding Symptom Perception, Preventive Care-Seeking, and Their Impact on Cervical Cancer Screening Among Vietnamese American Women
Status: Enrolling
Updated: 1/25/2018
OHSU Knight Cancer Institute
mi
from
Portland, OR
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
Sarasota Memorial Hospital
mi
from
Sarasota, FL
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
Sarasota Memorial Hospital
mi
from
Sarasota, FL
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
Rush University Medical Center
mi
from
Chicago, IL
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
AnMedical Health Cancer Center
mi
from
Anderson, SC
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
AnMedical Health Cancer Center
mi
from
Anderson, SC
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
Huntsman Cancer Institute at University of Utah
mi
from
Salt Lake City, UT
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
Huntsman Cancer Institute at University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
The Hartford Hospital
mi
from
Hartford, CT
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
The Hartford Hospital
mi
from
Hartford, CT
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
The Hospital of Central Connecticut
mi
from
New Britain, CT
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
The Hospital of Central Connecticut
mi
from
New Britain, CT
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
Memorial University Medical Center
mi
from
Savannah, GA
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
Memorial University Medical Center
mi
from
Savannah, GA
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
Sudarshan K Sharma MD Limted-Gynecologic Oncology
mi
from
Hinsdale, IL
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
Sudarshan K Sharma MD Limted-Gynecologic Oncology
mi
from
Hinsdale, IL
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
Memorial Medical Center
mi
from
Springfield, IL
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
Memorial Medical Center
mi
from
Springfield, IL
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
McFarland Clinic PC-William R Bliss Cancer Center
mi
from
Ames, IA
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
McFarland Clinic PC-William R Bliss Cancer Center
mi
from
Ames, IA
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
Iowa Methodist Medical Center
mi
from
Des Moines, IA
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
Iowa Methodist Medical Center
mi
from
Des Moines, IA
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
Iowa-Wide Oncology Research Coalition NCORP
mi
from
Des Moines, IA
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
Iowa-Wide Oncology Research Coalition NCORP
mi
from
Des Moines, IA
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
Medical Oncology and Hematology Associates-Des Moines
mi
from
Des Moines, IA
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
Medical Oncology and Hematology Associates-Des Moines
mi
from
Des Moines, IA
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
Medical Oncology and Hematology Associates-Laurel
mi
from
Des Moines, IA
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
Medical Oncology and Hematology Associates-Laurel
mi
from
Des Moines, IA
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
Mercy Medical Center - Des Moines
mi
from
Des Moines, IA
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
Mercy Medical Center - Des Moines
mi
from
Des Moines, IA
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
Iowa Lutheran Hospital
mi
from
Des Moines, IA
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
Iowa Lutheran Hospital
mi
from
Des Moines, IA
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
Maine Medical Center-Bramhall Campus
mi
from
Portland, ME
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
Maine Medical Center-Bramhall Campus
mi
from
Portland, ME
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
University of Mississippi Medical Center
mi
from
Jackson, MS
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
University of Mississippi Medical Center
mi
from
Jackson, MS
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
Cox Medical Center South
mi
from
Springfield, MO
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
Cox Medical Center South
mi
from
Springfield, MO
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
Nebraska Methodist Hospital
mi
from
Omaha, NE
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
Nebraska Methodist Hospital
mi
from
Omaha, NE
Click here to add this to my saved trials
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated:  1/26/2018
Carolinas Medical Center / Levine Cancer Institute
mi
from
Charlotte, NC
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium
Status: Enrolling
Updated: 1/26/2018
Carolinas Medical Center / Levine Cancer Institute
mi
from
Charlotte, NC
Click here to add this to my saved trials